Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL804146 | 1.00 | DPP4 (0.54) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL16967371 | 1.00 | DPP4 (0.54) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL3886489 | 1.00 | DPP4 (0.54) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL5862033 | 1.00 | DPP4 (0.54) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL4674647 | 1.00 | DPP4 (0.54) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL7415779 | 1.00 | DPP4 (0.54) | DPP4LMNAADRA2AADRA2CHIF1A | |
| Hydrochloric Acid SCHEMBL5860905 | 0.98 | DPP4 (0.52) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL7710838 | 0.85 | DPP4 (0.52) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL4676515 | 0.85 | ALOX5 (0.53) | DPP4LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL25178201 | 0.83 | ESR1 (0.46) | LMNAHIF1AKDM4ECYP2D6SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103980141-A | Xtandi synthesis method | UNIV SHANDONG | 2014-08-13 | — | — | CN | claimed |
| WO-2021081110-A2 | PEPTIDES AND USE THEREOF | ANEXIGEN, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| CN-107954936-A | A kind of method for preparing deuterated Imidazole diketone compound | 成都海创药业有限公司 | 2018-04-24 | — | — | CN | disclosed |
| CN-104470895-B | The purposes of N [3 (2 carboxy ethyl) phenyl] piperidinyl-1 yl acetamide derivatives and its activator as soluble guanylate cyclase | 拜耳制药股份公司 | 2017-04-05 | — | — | CN | disclosed |
| CN-106164052-A | For the method preparing grace miscellaneous Shandong amine | 赞蒂瓦有限合伙公司 | 2016-11-23 | — | — | CN | disclosed |
| CN-104803919-A | Preparation method of enzalutamide intermediate F | SHANGHAI INST PHARM INDUSTRY | 2015-07-29 | — | — | CN | disclosed |
| CN-104803918-A | Preparation method of enzalutamide | SHANGHAI INST PHARM INDUSTRY | 2015-07-29 | — | — | CN | disclosed |
| CN-103980141-A | Xtandi synthesis method | UNIV SHANDONG | 2014-08-13 | — | — | CN | disclosed |
| CN-103108549-A | Method for synthesizing diarylthiohydantoin and diarylhydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS INC | 2013-05-15 | — | — | CN | disclosed |
| US-20120071664-A1 | BETA-AMINO ACIDS AND METHODS AND INTERMEDIATES FOR MAKING SAME | NDSU RESEARCH FOUNDATION (US) | 2012-03-22 | — | — | US | disclosed |
| US-8003806-B2 | Integrin antagonists useful as anticancer agents | OSI Pharmaceuticals, LLC (US) | 2011-08-23 | — | — | US | disclosed |
| EP-1686999-B1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| EP-1828144-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| CN-1905884-A | Pyrazole derivatives as inhibitors of receptor tyrosyne kinases | ASTRAZENECA AB (SE) | 2007-01-31 | — | — | CN | disclosed |
| US-20070010579-A1 | Copper salts of organic acids and use thereof as fungicides | ISARGO S.P.A. (IT) | 2007-01-11 | — | — | US | disclosed |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ALCATEL LUCENT (FR) | 2006-06-01 | — | — | US | disclosed |
| WO-2006053342-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-5856311-A | Derivatives of β-aminopropionic acid with a fungicidal activity | ISAGRO RICERCA SRL (IT) | 1999-01-05 | — | — | US | disclosed |
| EP-0843967-A1 | Use of Beta-aminopropionic acid derivatives as fungicides | ISAGRO RICERCA S.r.l. (IT) | 1998-05-27 | — | — | EP | disclosed |
| EP-0718280-A2 | Derivatives of beta-aminopropionic acid with a fungicidal activity | ISAGRO RICERCA S.r.l. (IT) | 1996-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071664-A1 | BETA-AMINO ACIDS AND METHODS AND INTERMEDIATES FOR MAKING SAME | BCAT1, BCAT2, DAO | DPP4 2087/4885LMNA 755/4885ADRA2A 424/4885 |
| US-20070010579-A1 | Copper salts of organic acids and use thereof as fungicides | AOC3, AOC2, AOC1 | DPP4 2756/4885LMNA 4331/4885ADRA2A 3024/4885 |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ITGB5, ITGA5, ITGB1 | DPP4 3614/4885LMNA 1740/4885ADRA2A 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.